XML 66 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues:      
Revenues $ 788,087 $ 451,240 $ 161,626
Operating expenses:      
Cost of sales 7,428 4,889 1,254
Research and development 200,042 155,774 91,827
Acquired in-process research and development 154,272 4,750 30,000
Sales, general and administrative 354,062 248,932 169,906
Total operating expenses 715,804 414,345 292,987
Operating income (loss) 72,283 36,895 (131,361)
Other (expense) income:      
Interest expense (31,963) (30,530) (19,523)
Unrealized loss on restricted equity securities (12,987) 0 0
Investment income and other, net 19,209 15,476 8,342
Total other expense, net (25,741) (15,054) (11,181)
Income (loss) before provision for income taxes 46,542 21,841 (142,542)
Provision for income taxes 9,530 730  
Net income (loss) 37,012 21,111 (142,542)
Unrealized gain (loss) on marketable securities 3,345 (82) (1,532)
Comprehensive income (loss) $ 40,357 $ 21,029 $ (144,074)
Net income (loss) per share, basic $ 0.40 $ 0.23 $ (1.62)
Net income (loss) per share, diluted $ 0.39 $ 0.22 $ (1.62)
Weighted average common shares outstanding, basic 91,627,000 90,235,000 88,089,000
Weighted average common shares outstanding, diluted 95,732,000 95,386,000 88,089,000
Product sales, net      
Revenues:      
Revenues $ 752,900 $ 409,608 $ 116,626
Collaboration revenue      
Revenues:      
Revenues $ 35,187 $ 41,632 $ 45,000